Published in Oncogene on March 16, 2006
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics (2010) 2.26
Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev (2007) 1.49
Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer (2013) 1.26
Phosphorylation of activation function-1 regulates proteasome-dependent nuclear mobility and E6-associated protein ubiquitin ligase recruitment to the estrogen receptor beta. Mol Endocrinol (2007) 1.08
Specific activity of class II histone deacetylases in human breast cancer cells. Mol Cancer Res (2008) 1.07
Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer. PLoS One (2012) 1.00
Acquisition of sexual receptivity: roles of chromatin acetylation, estrogen receptor-alpha, and ovarian hormones. Endocrinology (2011) 0.90
Acetylation and nuclear receptor action. J Steroid Biochem Mol Biol (2010) 0.89
Tamoxifen resistance and epigenetic modifications in breast cancer cell lines. Curr Med Chem (2007) 0.89
Activation of ERα signaling differentially modulates IFN-γ induced HLA-class II expression in breast cancer cells. PLoS One (2014) 0.87
Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies? J Biomed Biotechnol (2010) 0.86
Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast. J Breast Cancer (2014) 0.85
Tamoxifen increases nuclear respiratory factor 1 transcription by activating estrogen receptor beta and AP-1 recruitment to adjacent promoter binding sites. FASEB J (2011) 0.85
Experience-facilitated improvements in pup retrieval; evidence for an epigenetic effect. Horm Behav (2012) 0.82
Histone deacetylase inhibition induces long-lasting changes in maternal behavior and gene expression in female mice. Endocrinology (2014) 0.80
The silent estrogen receptor--can we make it speak? Cancer Biol Ther (2009) 0.79
EF24 prevents rotenone-induced estrogenic status alteration in breast cancer. Cell Biol Int (2013) 0.76
A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A (1998) 24.58
Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst (2000) 5.21
Formation of the androgen receptor transcription complex. Mol Cell (2002) 4.93
Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res (1988) 2.90
Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res (2004) 2.67
Histone deacetylase 1 can repress transcription by binding to Sp1. Mol Cell Biol (1999) 2.53
Role of estrogen receptor beta in estrogen action. Annu Rev Physiol (2001) 2.40
p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem (2000) 2.31
Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res (2001) 2.21
ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology (2001) 2.18
Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol Cell Endocrinol (2003) 2.17
Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem (2001) 2.16
Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res (2001) 2.15
Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem (1999) 2.14
Minireview: nuclear receptor coactivators--an update. Endocrinology (2002) 2.04
Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res (2001) 1.85
Histone deacetylase as a therapeutic target. Trends Endocrinol Metab (2001) 1.83
Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res (2000) 1.70
Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol (2005) 1.67
Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs (2002) 1.62
Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett (2004) 1.45
The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene (2004) 1.38
Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res (1998) 1.37
Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res (2000) 1.36
Transcription activation by the human estrogen receptor subtype beta (ER beta) studied with ER beta and ER alpha receptor chimeras. Endocrinology (1998) 1.36
A comparison of transcriptional activation by ER alpha and ER beta. J Steroid Biochem Mol Biol (1999) 1.31
A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. Proc Natl Acad Sci U S A (1997) 1.15
Steroid receptor coactivator-1 (SRC-1) enhances ligand-dependent and receptor-dependent cell-free transcription of chromatin. Proc Natl Acad Sci U S A (1999) 1.09
Oestrogen receptor alpha increases p21(WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells. J Endocrinol (2003) 1.05
PPARgamma controls cell proliferation and apoptosis in an RB-dependent manner. Oncogene (2003) 1.05
Chromatin exposes intrinsic differences in the transcriptional activities of estrogen receptors alpha and beta. EMBO J (2003) 1.04
Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochem Pharmacol (2004) 1.03
n-Butyrate effects thyroid hormone stimulation of prolactin production and mRNA levels in GH1 cells. J Biol Chem (1984) 0.85
Associated effects of sodium butyrate on histone acetylation and estrogen receptor in the human breast cancer cell line MCF-7. Biochem Biophys Res Commun (1984) 0.85
Quantitation of estradiol receptors alpha and beta and progesterone receptors in human breast tumors by real-time reverse transcription-polymerase chain reaction. Correlation with protein assays. Biochem Pharmacol (2002) 0.82
The effects of histone acetylation on estrogen responsiveness in MCF-7 cells. Endocrine (1999) 0.78
Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell (2001) 4.78
Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci U S A (1986) 4.51
Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem (2000) 3.34
Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem (2001) 3.24
An implantable guide-screw system for brain tumor studies in small animals. J Neurosurg (2000) 2.50
Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci U S A (1994) 2.41
Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry (1997) 2.32
Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem (1994) 2.30
Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem (2001) 2.16
Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol (1996) 1.99
Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol (1996) 1.96
Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol Endocrinol (1998) 1.95
Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology (1999) 1.93
Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer (2004) 1.84
Activation of estrogen receptor-alpha by the heavy metal cadmium. Mol Endocrinol (2000) 1.83
An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc Natl Acad Sci U S A (1999) 1.79
Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res (1987) 1.78
The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol (1999) 1.74
A systematic study of HLA class II-beta DNA restriction fragments in insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A (1985) 1.69
Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res (1984) 1.66
Estrogen action in vitro. Induction of the synthesis of a specific uterine protein. J Biol Chem (1972) 1.66
Estrogenic activity of the insecticide chlordecone (Kepone) and interaction with uterine estrogen receptors. Proc Natl Acad Sci U S A (1979) 1.63
A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology (2000) 1.59
Estrogen receptor regulation of the Na+/H+ exchange regulatory factor. Endocrinology (1999) 1.56
Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol Endocrinol (1993) 1.56
Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance. Oncogene (2011) 1.51
Regulation of progesterone receptor messenger ribonucleic acid and protein levels in MCF-7 cells by estradiol: analysis of estrogen's effect on progesterone receptor synthesis and degradation. Endocrinology (1988) 1.51
Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology (2000) 1.50
Spinal rehabilitation by work tolerance based on objective physical capacity assessment of dysfunction. A prospective study with control subjects and twelve-month review. Spine (Phila Pa 1976) (1990) 1.47
Characterization of rubella virus-specific antibody responses by using a new synthetic peptide-based enzyme-linked immunosorbent assay. J Clin Microbiol (1992) 1.46
Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis (2006) 1.45
[Chronic urticaria and autoimmune thyroid diseases]. Ann Dermatol Venereol (1995) 1.43
Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. Proc Natl Acad Sci U S A (1996) 1.43
Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant (2006) 1.42
Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J Steroid Biochem (1982) 1.41
Structure-function analysis of the hormone binding domain of the human estrogen receptor by region-specific mutagenesis and phenotypic screening in yeast. J Biol Chem (1993) 1.40
Estrogen and antiestrogen action in reproductive tissues and tumors. Recent Prog Horm Res (1979) 1.39
RIP-140 interacts with multiple nuclear receptors by means of two distinct sites. Mol Cell Biol (1996) 1.39
Zearalenones: characterization of the estrogenic potencies and receptor interactions of a series of fungal beta-resorcylic acid lactones. Endocrinology (1979) 1.36
Estrogen-induced lysosomal proteases secreted by breast cancer cells: a role in carcinogenesis? J Cell Biochem (1987) 1.36
Transcription activation by the human estrogen receptor subtype beta (ER beta) studied with ER beta and ER alpha receptor chimeras. Endocrinology (1998) 1.36
Circadian expression of the steroid 15 alpha-hydroxylase (Cyp2a4) and coumarin 7-hydroxylase (Cyp2a5) genes in mouse liver is regulated by the PAR leucine zipper transcription factor DBP. Mol Cell Biol (1999) 1.34
HLA genotype studies in juvenile insulin-dependent diabetes. Diabetologia (1980) 1.34
Progesterone receptor regulation in uterine cells: stimulation by estrogen, cyclic adenosine 3',5'-monophosphate, and insulin-like growth factor I and suppression by antiestrogens and protein kinase inhibitors. Endocrinology (1991) 1.34
Nuclear hormone receptors: ligand-activated regulators of transcription and diverse cell responses. Chem Biol (1996) 1.32
Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog Horm Res (2000) 1.29
Transcriptional activities of the orphan nuclear receptor ERR alpha (estrogen receptor-related receptor-alpha). Mol Endocrinol (1999) 1.28
Identification of multiple, widely spaced estrogen-responsive regions in the rat progesterone receptor gene. Mol Endocrinol (1994) 1.27
Effects of estrogens and antiestrogens on estrogen receptor dynamics and the induction of progesterone receptor in MCF-7 human breast cancer cells. Cancer Res (1982) 1.27
The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol Endocrinol (1995) 1.27
Estrogen action and male fertility: roles of the sodium/hydrogen exchanger-3 and fluid reabsorption in reproductive tract function. Proc Natl Acad Sci U S A (2001) 1.26
Dynamics of steroid hormone receptor action. Annu Rev Physiol (1980) 1.25
Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation (2001) 1.25
Cloning of the rat progesterone receptor gene 5'-region and identification of two functionally distinct promoters. Mol Endocrinol (1993) 1.24
Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome. Ann Rheum Dis (2005) 1.24
Efficient and highly selective covalent labeling of the estrogen receptor with [3H]tamoxifen aziridine. J Biol Chem (1983) 1.24
Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor. Proc Natl Acad Sci U S A (1995) 1.23
Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res (1990) 1.23
Analysis of estrogen receptor interaction with a repressor of estrogen receptor activity (REA) and the regulation of estrogen receptor transcriptional activity by REA. J Biol Chem (2000) 1.22
Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes. Mol Endocrinol (1997) 1.22
Inhibitory cross-talk between steroid hormone receptors: differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist- and antagonist-occupied progestin receptors. Mol Cell Biol (1995) 1.22
Powerful dominant negative mutants of the human estrogen receptor. J Biol Chem (1993) 1.21
Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene (2010) 1.21
The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens. Proc Natl Acad Sci U S A (1997) 1.20
HLA haplotype study of 53 juvenile insulin-dependent diabetic (I.D.D.) families. Tissue Antigens (1982) 1.19
Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc Natl Acad Sci U S A (1989) 1.19
Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation. J Biol Chem (1996) 1.18
Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists, and growth factors. Mol Endocrinol (1989) 1.18
HLA-DR restricted peptide candidates for bee venom immunotherapy. J Immunol (2000) 1.18
Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. Mol Endocrinol (1988) 1.18
Synergistic activation of estrogen receptor-mediated transcription by estradiol and protein kinase activators. Mol Endocrinol (1993) 1.17
Genomic diversity of natural killer cell receptor genes in three populations. Tissue Antigens (2001) 1.15
Prothymosin alpha selectively enhances estrogen receptor transcriptional activity by interacting with a repressor of estrogen receptor activity. Mol Cell Biol (2000) 1.15
Differential DNA-binding abilities of estrogen receptor occupied with two classes of antiestrogens: studies using human estrogen receptor overexpressed in mammalian cells. Nucleic Acids Res (1991) 1.14
Characterization of the proximal estrogen-responsive element of human cathepsin D gene. Mol Endocrinol (1994) 1.14
Opposing functions of ATF2 and Fos-like transcription factors in c-Jun-mediated myogenin expression and terminal differentiation of avian myoblasts. Oncogene (2001) 1.14
Antiestrogen-binding sites distinct from the estrogen receptor: subecellular localization, ligand specificity, and distribution in tissues of the rat. Endocrinology (1983) 1.13
Caveolin-1 potentiates estrogen receptor alpha (ERalpha) signaling. caveolin-1 drives ligand-independent nuclear translocation and activation of ERalpha. J Biol Chem (1999) 1.13
Characterization and quantitation of antiestrogen binding sites in estrogen receptor-positive and -negative human breast cancer cell lines. Cancer Res (1983) 1.12
Anti-estrogen interaction with uterine estrogen receptors. Studies with a radiolabeled anti-estrogen (CI-628). J Biol Chem (1978) 1.11
Mechanical and barrier properties of cross-linked soy and whey protein based films. J Agric Food Chem (2001) 1.11
Differential interaction of nuclear receptors with the putative human transcriptional coactivator hTIF1. J Biol Chem (1997) 1.11
Identification of cysteine 530 as the covalent attachment site of an affinity-labeling estrogen (ketononestrol aziridine) and antiestrogen (tamoxifen aziridine) in the human estrogen receptor. J Biol Chem (1989) 1.10
A natural transactivation mutation in the thyroid hormone beta receptor: impaired interaction with putative transcriptional mediators. Proc Natl Acad Sci U S A (1997) 1.10
Analysis of HLA class I genes with restriction endonuclease fragments: implications for polymorphism of the human major histocompatibility complex. Proc Natl Acad Sci U S A (1983) 1.09
Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells. Mol Cell Endocrinol (1999) 1.09
Examination of the DNA-binding ability of estrogen receptor in whole cells: implications for hormone-independent transactivation and the actions of antiestrogens. Mol Cell Biol (1992) 1.09
Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen selectivity and promoter dependence. Mol Endocrinol (1994) 1.08
Identification of amino acids in the hormone binding domain of the human estrogen receptor important in estrogen binding. J Biol Chem (1996) 1.08
Estrogen receptor subtype-selective ligands: asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl- 5,6,11, 12-tetrahydrochrysenes. J Med Chem (1999) 1.07
Antiestrogen action in the uterus: biological ineffectiveness of nuclear bound estradiol after antiestrogen. Endocrinology (1975) 1.07
Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. J Mol Endocrinol (1999) 1.06
Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. Mol Endocrinol (1999) 1.06
Progesterone receptor regulation in T47D human breast cancer cells: analysis by density labeling of progesterone receptor synthesis and degradation and their modulation by progestin. Endocrinology (1988) 1.06
Human estrogen receptor beta-specific monoclonal antibodies: characterization and use in studies of estrogen receptor beta protein expression in reproductive tissues. Mol Cell Endocrinol (2001) 1.05
Activation of estrogen receptor beta is a prerequisite for estrogen-dependent upregulation of nitric oxide synthases in neonatal rat cardiac myocytes. FEBS Lett (2001) 1.05
Mutagenesis of cysteines in the hormone binding domain of the human estrogen receptor. Alterations in binding and transcriptional activation by covalently and reversibly attaching ligands. J Biol Chem (1991) 1.05
Oestrogen receptor alpha increases p21(WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells. J Endocrinol (2003) 1.05